Adaptive Biotechnologies Corp

Adaptive Biotechnologies reports $94M revenue, first profitable MRD quarter, and plans to scale clonoSEQ® while boosting investor engagement worldwide.

Adaptive Biotechnologies reported a Q1 2025 loss of $0.293 per share, but exceeded revenue estimates with $42.7 million in revenue, a 1.93% increase from the same quarter last year.

Adaptive Biotechnologies Corp reported a Q1 loss, but exceeded revenue expectations, sparking cautious optimism as the company navigates a critical juncture in its financial health.

Adaptive Biotechnologies Corp’s Q1 2025 earnings are expected to reveal whether the company can turn its financial narrative around, despite persistent losses and a promising revenue outlook.